Vascepa/Vazkepa significantly reduced STEMI by 40% and NSTEMI by 27%

Ireland-headquartered Amarin Corporation (Nasdaq: AMRN) today announced that new REDUCE-IT data show that fish oil-based drug Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment elevation myocardial infarction (STEMI), non-ST segment elevated myocardial infarction (NSTEMI), and other MI subtypes in patients with established cardiovascular disease (CVD) or diabetes with risk factors.

The REDUCE-IT data show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo.  IPE also significantly reduced NSTEMI by 27%. These data were presented today during a Late-Breaking Science Session at the European Society of Cardiology (ESC) Congress 2022 in Barcelona, Spain.

“This analysis of REDUCE-IT clearly shows that IPE 4g/day as an adjunct to statin therapy in high-risk patients with residual hypertriglyceridemia provides a large and significant reduction in heart attacks,” said Dr Deepak Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and principal investigator of the REDUCE-IT trial, adding: “Importantly, these new data show a significant reduction in the most important type of heart attack known as STEMI, as well as other MI subtypes.”